***
material type: Blood samples
test content: Safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19
testing unit: Pfizer
single sample quantity: Up to 515 mL for Phase 1 participants, up to 110 mL for Phase 2/3 participants, 20 mL for unplanned convalescent visit, and 170 mL for select Phase 1 participants at Visit 5, 6, or 7
number of cases: N/A
total quantity: Up to 700 mL for select Phase 1 participants during the 24-month study period
unit/specification: mL
disposal plan for residual materials: N/A
***